Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Newsworthy01on Dec 13, 2017 7:17pm

289 Views

Post# 27151942

Kalytera is SO undervalued

This stock is the best kept secret. To be able to develop a CBD compound that both prevents and treats graft host disease is absolutely phenomenal. This really demonstrates the medicinal benefit of cannabis. And, Kalytera will likely be a phase 3 company by MIDDLE of 2018. Phase 3 status is RARE for companies and EXTREMELY VALUABLE. Watch the upward trajectory of this stock. There will be a lot of happy campers. I recommend that you contact the CEO to learn more about the company and the investment opportunity.

Bullboard Posts

Canadian artificial intelligence ETFs